Programs
- Cephalon Establishes the Frank Baldino, Jr. Endowed Scholarship Fund at the Temple University School of Medicine
- Cephalon Helps to Launch Framing Life With Lymphoma
- When Good Medicines Become Bad DrugsSM
- Cephalon to Match Employee Contributions to Aid Earthquake Relief in Haiti
- The Leukemia & Lymphoma Society Partnership - Light The Night
- Oncology Nursing Society Foundation Partnership
- National Organization for Rare Disorders Partnership
- Community Volunteers in Medicine
- The Franklin-Cephalon Partnership
- Federation of State Medical Boards
- The Partnership for a Drug-Free America
- Horst Witzel Award
- National Constitution Center Partnership
National Organization For Rare Disorders Partnership
Cephalon and NORD share a commitment to improving the lives of people with rare diseases and disorders.
The Orphan Drug Act of 1983 marked the passing of one of the most significant pieces of healthcare legislation ever signed into law in this country. It provided incentive for pharmaceutical companies to recover the expenses associated with discovery and development of new drugs to treat "rare" conditions – those which affect fewer than 20,000 people in the US.
The same year, the National Organization for Rare Disorders (NORD) was established to represent the interests of patients and families affected by rare diseases and disorders. NORD celebrated its 25th anniversary in 2008; it remains the most committed and recognized organization supporting patients with rare diseases through research, education, service and advocacy.
"NORD appreciates Cephalon's history of orphan product development and dedication to improving the lives of people with rare diseases for whom there are few, or no, treatment options," said Peter Saltonstall, President and Chief Executive Office at NORD. "Since NORD was founded, thousands of patients with rare diseases now have medications. On behalf of all patients with rare diseases, we are grateful to Cephalon and others for their commitment to the discovery and development of therapies to meet underserved medical needs."
Two of Cephalon's investigational therapies have orphan drug designation, as well as three of the Company's nine proprietary medicines – TRISENOX, for the treatment of relapsed acute promyelocytic leukemia; TREANDA, for the treatment of chronic lymphocytic leukemia; and PROVIGIL, for the treatment of narcolepsy.